BridgeMD
GLUTAMICS III
EU CTIS ID: 2024-513575-40-01
What this study is testing
To establish the efficacy of intravenous glutamate infusion to prevent acute kidney injury (AKI) after coronary artery bypass surgery (CABG) among high-risk patients without diabetes.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult patients without diabetes operated on heart-lung machine with CABG of at least two vessel disease or left main stenosis with or without a concomitant procedure and who either have EuroSCORE II ≥ 3.0 to which at least one cardiac or procedure related risk factor contribute or Left Ventricular Ejection Fraction ≤ 0.30 regardless of EuroSCORE II
You likely can't join if
- Diabetes; ambiguous food allergy known to have elicited flushing, headache, rash or asthma; age > 85 years; previous cardiac surgery; informed consent not possible because of critical condition or other reason; preoperative use of inotropic support or mechanical circulatory assist; preoperative dialysis or calculated Creatinine clearance < 30 mL/min; surgery without heart-lung machine (off-pump); concomitant Maze-procedure; surgery of ascending aorta necessitating circulatory arrest; surgery of both aortic and mitral valve.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.